CN109480285A - A kind of haematococcus pluvialis soft capsule - Google Patents
A kind of haematococcus pluvialis soft capsule Download PDFInfo
- Publication number
- CN109480285A CN109480285A CN201811500495.9A CN201811500495A CN109480285A CN 109480285 A CN109480285 A CN 109480285A CN 201811500495 A CN201811500495 A CN 201811500495A CN 109480285 A CN109480285 A CN 109480285A
- Authority
- CN
- China
- Prior art keywords
- astaxanthin
- ethyl acetate
- haematococcus pluvialis
- parts
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000168517 Haematococcus lacustris Species 0.000 title claims abstract description 39
- 239000007901 soft capsule Substances 0.000 title claims abstract description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 105
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 72
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 72
- 239000001168 astaxanthin Substances 0.000 claims abstract description 72
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 72
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 72
- 230000001376 precipitating effect Effects 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000006228 supernatant Substances 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 238000002525 ultrasonication Methods 0.000 claims abstract description 8
- 108010059892 Cellulase Proteins 0.000 claims abstract description 7
- 229940106157 cellulase Drugs 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims abstract description 7
- 238000004321 preservation Methods 0.000 claims abstract description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 24
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000003921 oil Substances 0.000 claims description 13
- 235000019198 oils Nutrition 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 11
- 239000003813 safflower oil Substances 0.000 claims description 10
- 108010010803 Gelatin Proteins 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000008273 gelatin Substances 0.000 claims description 8
- 229920000159 gelatin Polymers 0.000 claims description 8
- 235000019322 gelatine Nutrition 0.000 claims description 8
- 235000011852 gelatine desserts Nutrition 0.000 claims description 8
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 8
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 claims description 8
- 239000008213 purified water Substances 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 8
- 239000000741 silica gel Substances 0.000 claims description 8
- 229910002027 silica gel Inorganic materials 0.000 claims description 8
- 239000004408 titanium dioxide Substances 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000013517 stratification Methods 0.000 claims description 6
- 238000005292 vacuum distillation Methods 0.000 claims description 6
- 238000003825 pressing Methods 0.000 claims 1
- 239000000284 extract Substances 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 8
- 238000000605 extraction Methods 0.000 abstract description 6
- 238000011084 recovery Methods 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 2
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 229960001866 silicon dioxide Drugs 0.000 description 7
- 235000005713 safflower oil Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 241000168525 Haematococcus Species 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 241000195493 Cryptophyta Species 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000195627 Chlamydomonadales Species 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention relates to field of health care food, the astaxanthin extracted more particularly to a kind of haematococcus pluvialis and its application, it is an object of that present invention to provide the extracting method of the astaxanthin of haematococcus pluvialis extraction and the haematococcus pluvialis soft capsule prepared with the astaxanthin of the preparation, the astaxanthin of this method preparation has the characteristics that recovery rate height and the column chromatographic purifying rate of recovery.A kind of astaxanthin that haematococcus pluvialis extracts, preparation method is in accordance with the following steps: after haematococcus pluvialis drying and crushing, isometric ethyl acetate is added and carries out cryogrinding, then the water of 8-10 times of quality is added, and cellulase and pectase ultrasonication 1-2min, heat preservation hydrolysis, it is centrifugated supernatant and precipitating, ethyl acetate is added in precipitating to extract, after the ethyl acetate of ethyl acetate and precipitating extraction in supernatant is mixed, freeze-dried, purifying, obtains astaxanthin oil.
Description
Technical field
The present invention relates to field of health care food, and in particular to a kind of haematococcus pluvialis soft capsule and Astaxanthin In Haematococcus Pluvialis
Preparation method.
Background technique
Astaxanthin is a kind of pigment of carotenoids, entitled 3, the 3'- dihydroxy-beta carotene -4,4'- bis- of chemistry
Ketone is naturally present in the biology such as algae, shrimp, crab and salmon.Natural astaxanthin is a kind of with the active class Hu of high anti-oxidation
Radish element, there is the anti-lipid peroxidation of 10 times of beta carotene antioxidant effects and 550 times of vitamin Es to react special for it
Property, it cannot be synthesized in animal body, but it is substance necessary to human body and animal life activity.Studies have shown that astaxanthin
The immunity of organism can be enhanced, the rehabilitations such as cardiovascular disease, immune system, inflammation and nervus retrogression can be assisted, together
When have the function of anti-aging and repair ultraviolet injury, can be widely applied to aquatic products and livestock-raising, food and cosmetics with
And medicinal industry, there is huge market potential.
Haematococcus pluvialis is a kind of single celled eukaryotic green alga, is subordinate to Chlorophyta, volvocales, haematococcus section, haematococcus.By
Largely astaxanthin can be accumulated in the algae and red is presented, therefore is named haematococcus.Astaxanthin can be largely accumulated under particular circumstances,
Its content is up to the 1.5-4% of dry cell weight, and therefore, haematococcus pluvialis is to generally acknowledge the best life for natural astaxanthin exploitation
Goods and materials source, it has also become the research hotspot of international natural astaxanthin industry.Haematococcus pluvialis soft capsule is logical as nutritional health food
U.S. FDA approval has been crossed, the oxidative damage of LDL- cholesterol, protection skin can resist ultraviolet radiation damage effectively in pre- resistant to blood
And alleviate age-related macular degeneration etc..It was eaten through Ministry of Public Health's approval haematococcus pluvialis as new resources in 2010 in China
Product, therefore Haematococcus pluvialis production natural astaxanthin is developed with huge market potential.
At present in the method for Haematococcus pluvialis production natural astaxanthin, generally include grinding, broken wall, organic solvent extract and
Purifying and etc..Currently, most common astaxanthin purification process is column chromatography, commonly by continuous silica gel medium pressure column, polyamides
Amine column etc..Wherein, silicagel column will not have an impact astaxanthin, but the rate of recovery is low, generally be not higher than 70%.Extraction process
High temperature oxygen ambient is then another key factor of astaxanthin loss.The method that current decompression extracts can reduce mentioning for astaxanthin
Temperature is taken, guarantees the recovery rate and stability of astaxanthin, but temperature condition at least will also be controlled at 60 DEG C or so.
Summary of the invention
It is an object of that present invention to provide the extraction sides of the soft capsule of haematococcus pluvialis preparation and Astaxanthin In Haematococcus Pluvialis
The astaxanthin of method, this method preparation has the characteristics that recovery rate height and the column chromatographic purifying rate of recovery.
The astaxanthin that a kind of haematococcus pluvialis extracts, preparation method in accordance with the following steps:
1) isometric ethyl acetate after haematococcus pluvialis drying and crushing, will be added and carries out cryogrinding, obtain mixture
The water of 8-10 times of quality is added into mixture A, obtains mixture B by A,
2) cellulase 0.4-0.5% and pectase 0.2-0.3% is added by the quality of mixture B, keeps initial temperature
Not higher than 5 DEG C, with the ultrasonication 1-2min of 300W, 22-25KHz, then temperature is controlled and hydrolyzes 5- in 37-40 DEG C of heat preservation
10min is centrifugated supernatant and precipitating, the whole stirring of step 2), mixing speed 500-1000r/min；
3) after supernatant stratification, liquid separation, vacuum distillation obtains the ethyl acetate A containing astaxanthin；
4) ethyl acetate is added in precipitating to extract, separates, obtains the ethyl acetate B containing astaxanthin；
5) after mixing ethyl acetate A and B containing astaxanthin, freeze-drying is chromatographed pure using continuous silica gel medium pressure column
Change, obtains astaxanthin oil.
Further, the astaxanthin oil can be used for preparing haematococcus pluvialis soft capsule, raw materials used proportion by weight
Are as follows: 100-120 parts of astaxanthin oil, 370-400 parts of safflower seed oil.
Further, the raw material of used soft capsule shell includes to measure in parts by mass: 100-120 parts of gelatin, glycerol
50-60 parts, 0.3-0.4 parts of titanium dioxide, 0.01 part of Brown Ferric Oxide, 100-120 parts of purified water
The invention has the following beneficial effects:
Haematococcus pluvialis soft capsule of the invention has effects that anti-oxidant, anti-aging, protection eyesight and cardiovascular and cerebrovascular.It adopts
It uses astaxanthin oil and safflower seed oil as primary raw material, astaxanthin oil is protected using safflower seed oil, ensure that astaxanthin
The activity of oil.
The present invention prepares the process of astaxanthin, and whole temperature is lower than 40 DEG C, and astaxanthin almost damage by non-oxidation in extraction process
It loses.The ethyl acetate of the first step grinds the effect by preextraction astaxanthin, and during the ultrasonication of second step, prawn
Green element is protected, the astaxanthin that preventing portion sub-dip goes out, and is destroyed in the localized hyperthermia that ultrasonic wave effect generates, by super
After sonication and enzymatic treatment, using onestep extraction, 97% astaxanthin can be obtained.Also, purifying is using continuous middle pressure silicon
Plastic column chromatography, purification process is nonnutritive to astaxanthin, ensure that the bioactivity of product astaxanthin.
Specific embodiment
The following examples can make those skilled in the art that the present invention be more fully understood, but not limit in any way
The present invention.
Embodiment 1
A kind of haematococcus pluvialis soft capsule, raw materials used proportion by weight are as follows: 120 parts of astaxanthin oil, safflower seed oil 370
Part, 120 parts of gelatin, 60 parts of glycerol, 0.3 part of titanium dioxide, 0.01 part of Brown Ferric Oxide, 120 parts of purified water.
Embodiment 2
A kind of haematococcus pluvialis soft capsule, raw materials used proportion by weight are as follows: 120 parts of astaxanthin oil, safflower seed oil 375
Part, 110 parts of gelatin, 50 parts of glycerol, 0.4 part of titanium dioxide, 0.01 part of Brown Ferric Oxide, 110 parts of purified water.
Embodiment 3
A kind of haematococcus pluvialis soft capsule, raw materials used proportion by weight are as follows: 100 parts of astaxanthin oil, safflower seed oil 380
Part, 100 parts of gelatin, 55 parts of glycerol, 0.4 part of titanium dioxide, 0.01 part of Brown Ferric Oxide, 100 parts of purified water.
Embodiment 4
A kind of haematococcus pluvialis soft capsule, raw materials used proportion by weight are as follows: 110 parts of astaxanthin oil, safflower seed oil 400
Part, 105 parts of gelatin, 55 parts of glycerol, 0.35 part of titanium dioxide, 0.01 part of Brown Ferric Oxide, 115 parts of purified water.
Embodiment 5
A kind of haematococcus pluvialis soft capsule, raw materials used proportion by weight are as follows: 115 parts of astaxanthin oil, safflower seed oil 385
Part, 110 parts of gelatin, 55 parts of glycerol, 0.32 part of titanium dioxide, 0.01 part of Brown Ferric Oxide, 110 parts of purified water.
Embodiment 6
A kind of haematococcus pluvialis soft capsule, raw materials used proportion by weight are as follows: 120 parts of astaxanthin oil, safflower seed oil 390
Part, 120 parts of gelatin, 60 parts of glycerol, 0.4 part of titanium dioxide, 0.01 part of Brown Ferric Oxide, 100 parts of purified water.
Embodiment 7
The astaxanthin that a kind of haematococcus pluvialis extracts, preparation method in accordance with the following steps:
1) isometric ethyl acetate after haematococcus pluvialis drying and crushing, will be added and carries out cryogrinding, obtain mixture
The water of 8 times of quality is added into mixture A, obtains mixture B by A,
2) cellulase 0.4% and pectase 0.2% is added by the quality of mixture B, initial temperature is kept to be not higher than 5
DEG C, with the ultrasonication 1min of 300W, 22KHz, then temperature is controlled and hydrolyzes 8min, centrifuge separation in 37-40 DEG C of heat preservation
Supernatant and precipitating, the whole stirring of step 2), mixing speed 500r/min；
3) after supernatant stratification, liquid separation, vacuum distillation obtains the ethyl acetate A containing astaxanthin；
4) ethyl acetate is added in precipitating to extract, separates, obtains the ethyl acetate B containing astaxanthin；
5) after mixing ethyl acetate A and B containing astaxanthin, freeze-drying is chromatographed pure using continuous silica gel medium pressure column
Change, obtains astaxanthin oil.
Embodiment 8
The astaxanthin that a kind of haematococcus pluvialis extracts, preparation method in accordance with the following steps:
1) isometric ethyl acetate after haematococcus pluvialis drying and crushing, will be added and carries out cryogrinding, obtain mixture
The water of 8 times of quality is added into mixture A, obtains mixture B by A,
2) cellulase 0.4% and pectase 0.3% is added by the quality of mixture B, initial temperature is kept to be not higher than 5
DEG C, with the ultrasonication 1min of 300W, 25KHz, then temperature is controlled and hydrolyzes 5min, centrifuge separation in 37-40 DEG C of heat preservation
Supernatant and precipitating, the whole stirring of step 2), mixing speed 800r/min；
3) after supernatant stratification, liquid separation, vacuum distillation obtains the ethyl acetate A containing astaxanthin；
4) ethyl acetate is added in precipitating to extract, separates, obtains the ethyl acetate B containing astaxanthin；
5) after mixing ethyl acetate A and B containing astaxanthin, freeze-drying is chromatographed pure using continuous silica gel medium pressure column
Change, obtains astaxanthin oil.
Embodiment 9
The astaxanthin that a kind of haematococcus pluvialis extracts, preparation method in accordance with the following steps:
1) isometric ethyl acetate after haematococcus pluvialis drying and crushing, will be added and carries out cryogrinding, obtain mixture
The water of 10 times of quality is added into mixture A, obtains mixture B by A,
2) cellulase 0.5% and pectase 0.2% is added by the quality of mixture B, initial temperature is kept to be not higher than 5
DEG C, with the ultrasonication 1-2min of 300W, 22KHz, then temperature is controlled and hydrolyzes 5min, centrifugation point in 37-40 DEG C of heat preservation
From supernatant and precipitating, the whole stirring of step 2), mixing speed 500r/min；
3) after supernatant stratification, liquid separation, vacuum distillation obtains the ethyl acetate A containing astaxanthin；
4) ethyl acetate is added in precipitating to extract, separates, obtains the ethyl acetate B containing astaxanthin；
5) after mixing ethyl acetate A and B containing astaxanthin, freeze-drying is chromatographed pure using continuous silica gel medium pressure column
Change, obtains astaxanthin oil.
Embodiment 10
The astaxanthin that a kind of haematococcus pluvialis extracts, preparation method in accordance with the following steps:
1) isometric ethyl acetate after haematococcus pluvialis drying and crushing, will be added and carries out cryogrinding, obtain mixture
The water of 8 times of quality is added into mixture A, obtains mixture B by A,
2) cellulase 0.4% and pectase 0.3% is added by the quality of mixture B, initial temperature is kept to be not higher than 5
DEG C, with the ultrasonication 1-2min of 300W, 23KHz, then temperature is controlled and hydrolyzes 10min, centrifugation point in 37-40 DEG C of heat preservation
From supernatant and precipitating, the whole stirring of step 2), mixing speed 1000r/min；
3) after supernatant stratification, liquid separation, vacuum distillation obtains the ethyl acetate A containing astaxanthin；
4) ethyl acetate is added in precipitating to extract, separates, obtains the ethyl acetate B containing astaxanthin；
5) after mixing ethyl acetate A and B containing astaxanthin, freeze-drying is chromatographed pure using continuous silica gel medium pressure column
Change, obtains astaxanthin oil.
It will be understood by those skilled in the art that above embodiments are only exemplary embodiments, without departing substantially from spirit of the invention
In the case where range, a variety of variations can be carried out, replaced and changed.
Claims (3)
1. a kind of haematococcus pluvialis soft capsule, which is characterized in that content is made of the raw material of following proportion by weight:
100-120 parts of astaxanthin oil, 370-400 parts of safflower seed oil.
2. a kind of haematococcus pluvialis soft capsule according to claim 1, which is characterized in that the raw material of soft capsule shell includes pressing
Mass parts meter: 100-120 parts of gelatin, 50-60 parts of glycerol, 0.3-0.4 parts of titanium dioxide, 0.01 part of Brown Ferric Oxide, purified water
100-120 parts.
3. a kind of haematococcus pluvialis soft capsule according to claim 1, which is characterized in that
The astaxanthin oil preparation method is in accordance with the following steps:
1) isometric ethyl acetate after haematococcus pluvialis drying and crushing, will be added and carries out cryogrinding, obtain mixture A, to
The water of 8-10 times of quality is added in mixture A, obtains mixture B,
2) cellulase 0.4-0.5% and pectase 0.2-0.3% is added by the quality of mixture B, keeps initial temperature not high
In 5 DEG C, with the ultrasonication 1-2min of 300W, 22-25KHz, then temperature is controlled and hydrolyzes 5- in 37-40 DEG C of heat preservation
10min is centrifugated supernatant and precipitating, the whole stirring of step 2), mixing speed 500-1000r/min；
3) after supernatant stratification, liquid separation, vacuum distillation obtains the ethyl acetate A containing astaxanthin；
4) ethyl acetate is added in precipitating to extract, separates, obtains the ethyl acetate B containing astaxanthin；
5) after mixing ethyl acetate A and B containing astaxanthin, freeze-drying using continuous silica gel medium pressure column chromatographic purifying, is obtained
To astaxanthin oil.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811500495.9A CN109480285A (en) | 2018-12-10 | 2018-12-10 | A kind of haematococcus pluvialis soft capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811500495.9A CN109480285A (en) | 2018-12-10 | 2018-12-10 | A kind of haematococcus pluvialis soft capsule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109480285A true CN109480285A (en) | 2019-03-19 |
Family
ID=65698358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811500495.9A Pending CN109480285A (en) | 2018-12-10 | 2018-12-10 | A kind of haematococcus pluvialis soft capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109480285A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110713450A (en) * | 2019-10-17 | 2020-01-21 | 福建启元堂生物技术有限公司 | Astaxanthin extraction method based on haematococcus pluvialis |
| CN115299606A (en) * | 2022-09-14 | 2022-11-08 | 云南龙布瑞生物科技有限公司 | Method for separating and purifying endogenous pigment from fresh microalgae cells |
| CN117044940A (en) * | 2023-07-17 | 2023-11-14 | 青岛南极维康生物科技有限公司 | Krill oil haematococcus pluvialis and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101978975A (en) * | 2010-11-16 | 2011-02-23 | 云南绿A生物工程有限公司 | Haematococcus extract preparation, and preparation method and use thereof |
| CN103880726A (en) * | 2014-03-14 | 2014-06-25 | 山东省农业科学院农产品研究所 | Method for extracting astaxanthin in haematococcus pluvialis by adopting enzymolysis method and grinding method through organic solvent |
| CN106923334A (en) * | 2016-12-22 | 2017-07-07 | 云南爱尔康生物技术有限公司 | A kind of astaxanthin flexible glue capsule formula and preparation method thereof |
| CN107805215A (en) * | 2017-10-18 | 2018-03-16 | 海南三元星生物科技股份有限公司 | A kind of extracting method of astaxanthin |
| CN108902958A (en) * | 2018-07-20 | 2018-11-30 | 深圳市博奥生物科技有限公司 | A kind of astaxanthin soft capsule and preparation method thereof |
-
2018
- 2018-12-10 CN CN201811500495.9A patent/CN109480285A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101978975A (en) * | 2010-11-16 | 2011-02-23 | 云南绿A生物工程有限公司 | Haematococcus extract preparation, and preparation method and use thereof |
| CN103880726A (en) * | 2014-03-14 | 2014-06-25 | 山东省农业科学院农产品研究所 | Method for extracting astaxanthin in haematococcus pluvialis by adopting enzymolysis method and grinding method through organic solvent |
| CN106923334A (en) * | 2016-12-22 | 2017-07-07 | 云南爱尔康生物技术有限公司 | A kind of astaxanthin flexible glue capsule formula and preparation method thereof |
| CN107805215A (en) * | 2017-10-18 | 2018-03-16 | 海南三元星生物科技股份有限公司 | A kind of extracting method of astaxanthin |
| CN108902958A (en) * | 2018-07-20 | 2018-11-30 | 深圳市博奥生物科技有限公司 | A kind of astaxanthin soft capsule and preparation method thereof |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110713450A (en) * | 2019-10-17 | 2020-01-21 | 福建启元堂生物技术有限公司 | Astaxanthin extraction method based on haematococcus pluvialis |
| CN115299606A (en) * | 2022-09-14 | 2022-11-08 | 云南龙布瑞生物科技有限公司 | Method for separating and purifying endogenous pigment from fresh microalgae cells |
| CN115299606B (en) * | 2022-09-14 | 2024-02-02 | 云南龙布瑞生物科技有限公司 | Method for separating and purifying endogenous pigment from fresh microalgae cells |
| CN117044940A (en) * | 2023-07-17 | 2023-11-14 | 青岛南极维康生物科技有限公司 | Krill oil haematococcus pluvialis and preparation method thereof |
| CN117044940B (en) * | 2023-07-17 | 2024-05-28 | 青岛南极维康生物科技有限公司 | Krill oil haematococcus pluvialis and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lee et al. | Antioxidant Activities of Native Gwangyang Rubus coreanus Miq. | |
| Wu et al. | Bioactive substances and potentiality of marine microalgae | |
| CN109480285A (en) | A kind of haematococcus pluvialis soft capsule | |
| CN105055250B (en) | A kind of cosmetics containing phycocyanin and preparation method thereof | |
| Rodríguez-Sifuentes et al. | Importance of downstream processing of natural astaxanthin for pharmaceutical application | |
| CN104886707A (en) | Composite solid meal replacement health-preservation anti-cancer fruit and vegetable beverage and preparation method thereof | |
| CN104664527A (en) | Composition with effects of preventing and resisting cancer, resisting radiation and eliminating heavy metals in bodies | |
| CN105795418A (en) | Eyesight-improving spleen-tonifying pearl Poria honey and preparation method thereof | |
| CN110746515B (en) | Lycium barbarum polysaccharide, lycium barbarum red element and lycium barbarum polypeptide prepared by synchronous separation and preparation method thereof | |
| JP2021045127A (en) | Method for mass production of carotenoids | |
| CN105146273A (en) | Lycium ruthenicum anthocyanin soft capsules and preparation method thereof | |
| Das et al. | Ultrasound assisted extraction of food colorants: principle, mechanism, extraction technique and applications: a review on recent progress | |
| CN104382953A (en) | Extraction method of melanin in black fungi | |
| CN107232594A (en) | A kind of complex health care product of strengthen immunity | |
| CN104974071B (en) | A kind of preparation method of luteole | |
| CN108752252B (en) | Method for extracting and purifying astaxanthin in shrimp shells and crab shells by using neutral protease | |
| Mussagy et al. | Microbial astaxanthin: from bioprocessing to the market recognition | |
| Hans et al. | Platform molecules from algae by using supercritical CO2 and subcritical water extraction | |
| CN106692955A (en) | Seaweed extract healthcare product having anti-aging effect and preparation method of seaweed extract healthcare product | |
| CN110713450A (en) | Astaxanthin extraction method based on haematococcus pluvialis | |
| KR101578464B1 (en) | Antiaging cosmetic composition containing monascus fermented oil | |
| Hans et al. | Algal-derived physiologically active nutraceuticals: Dietary supplements, vitamins, carotenoids, fatty acids and other novel products | |
| CN107821923A (en) | The preparation method of microcapsules containing lycopene | |
| CN113693185A (en) | Blueberry solid beverage and preparation process thereof | |
| CN112898444A (en) | Method for preparing muramyl polysaccharide by using ganoderma lucidum spore powder raffinate, product and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190319 |
|
| RJ01 | Rejection of invention patent application after publication |